Ardent Health Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARDT research report →
Range $11 – $21
Price Chart
About the company
Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services within inpatient and ambulatory care settings.
- CEO
- Dave Caspers
- IPO
- 2024
- Employees
- 22,350
- HQ
- Brentwood, TN, US
Get TickerSpark's AI analysis on ARDT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.13B
- P/E
- 13.94
- Fwd P/E
- 14.16
- PEG
- -0.45
- P/S
- 0.32
- P/B
- 1.46
- EV/EBITDA
- 7.33
- Div Yield
- 0.00%
- Gross Margin
- 19.79%
- Op Margin
- 5.02%
- Net Margin
- 2.27%
- ROE
- 9.48%
- ROIC
- 5.89%
Latest fiscal year · YoY change
- Revenue
- $6.32B+6.0%
- Gross Profit
- $6.17B+25.0%
- Op Income
- $325.58M
- Net Income
- $135.81M-35.4%
- EPS
- $0.96-39.6%
- OCF Growth
- +49.4%
- FCF Growth
- +102.8%
- 52W High
- $18.57
- 52W Low
- $7.71
- 50D MA
- $12.57
- 200D MA
- $10.51
- Beta
- 0.72
- RSI (14)
- 49
- Avg Volume
- 698.72K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ardent Health delivered a strong third quarter with higher admissions, improved cost discipline and cash flow, then raised the low end of full-year adjusted EBITDA guidance while continuing to reshape its portfolio.· November 5, 2026
- Adjusted EBITDA was $138 million on revenue of $1.62 billion; operating cash flow was $122 million in the quarter.
- Adjusted admissions rose 2.9% year over year, ER visits grew 1.7%, and key access metrics improved sequentially.
- Salaries, wages and benefits expense fell 4.3% year over year; contract labor spend dropped 45% and was 2.0% of SWB.
- Management raised 2026 adjusted EBITDA guidance to $500 million-$535 million from $485 million-$535 million, while saying revenue remains biased to the low end of the $6.4 billion-$6.7 billion range.
- Ardent agreed to divest its Kansas hospital ownership, saying the asset was not a long-term strategic fit and that the deal should add 40 basis points to margin.
Third-quarter revenue was $1.62 billion and adjusted EBITDA was $138 million. Operating cash flow was $122 million in the quarter and $258 million year to date, up 5% from $247 million in the prior-year period. Adjusted admissions increased 2.9% year over year, ER visits grew 1.7%, SWB expense declined 4.3%, and contract labor spend fell 45% year over year; SWB was 39.9% of revenue, down 300 basis points from last year. Management raised 2026 adjusted EBITDA guidance to $500 million-$535 million from $485 million-$535 million, and said revenue is still expected toward the lower end of the $6.4 billion-$6.7 billion range. CapEx guidance moved to $210 million-$250 million from $225 million-$265 million. The company ended the quarter with $766 million of cash, $1.1 billion of debt, and total available liquidity of $1 billion.
Dave Caspers framed the quarter as evidence that Ardent is making tangible progress on more consistent execution, EBITDA growth, capital deployment and long-term shareholder value. He emphasized a three-part strategy: operational excellence, organic growth in core markets, and disciplined capital allocation. His tone was constructive and confident, especially around the IMPACT program, Capacity IQ, and the company’s ability to control the controllables despite a difficult industry backdrop. He also highlighted the Kansas divestiture as a disciplined portfolio move that improves the margin profile and frees up capital for higher-value growth.
Alfred Lumsdaine said Q3 was a “largely clean quarter” and described the results as a durable base for growth into 2027. He highlighted improved sequential volumes, better surgery trends, and expense discipline, including SWB down 4.3% year over year, contract labor down 45%, and professional fee growth slowing to 7.4% in Q3 versus 10.4% in Q2 and 12.9% in Q1. He also pointed to $122 million of operating cash flow in Q3, $258 million year to date, $49 million of Q3 CapEx, $11 million of buybacks in the quarter, $24 million repurchased year to date, and the board’s additional $25 million authorization. He noted the balance sheet ended Q3 with $766 million in cash, $1.1 billion in debt, and lease-adjusted net leverage of 2.5x.
Analysts focused on payer contracting, surgical volume weakness, M&A timing, CapEx, and how 2027 may be shaped by policy changes and the IMPACT program. Management said 2026 had an unusually high number of renewals and that the company is now 85% contracted for 2027 and 75% for 2028, with negotiations described as more contentious but consistent with the New Mexico outcome. On surgery, management said about half of the decline was from intentional rationalization, that some inpatient pressure reflects inpatient-to-outpatient migration and the inpatient-only list, and that the impact from that migration was around $1 million-$2 million. On growth and capital deployment, management said the M&A pipeline remains active but they are patient and disciplined, while CapEx guidance was trimmed without affecting maintenance or growth priorities; they also said the wrap of IMPACT into next year could translate to a $20 million-$25 million tailwind.
The call showed improving core demand, with admissions, ER visits, urgent care, imaging, and physician visits all moving positively or improving sequentially. Management sounded increasingly confident that cost actions and IMPACT are producing durable benefits, while the company still has significant liquidity and room to deploy capital into growth or M&A.
Surgical volumes remain soft, especially on the inpatient side, and management said some rationalization will continue over the next several quarters. Payer and policy pressure also remains a risk, with elevated denials, contentious re-contracting, exchange/self-pay mix pressure, and management flagging Medicaid work requirements and HIX-related headwinds as issues for next year.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 15.6%
- Shares Outstanding
- 140.94M
- Float Shares
- 21.97M
of shares held by institutions
142 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Chai Trust Co LLC | 77.25M | 0 |
| Ventas, Inc. | 9.34M | 0 |
| Blackrock, Inc. | 2.27M | ▲ 91.28K |
| Ameriprise Financial Inc | 2.11M | ▲ 333.87K |
| Goldentree Asset Management LP | 1.58M | ▼ 722.69K |
| Vanguard Group Inc | 1.50M | ▲ 151.69K |
| Aqr Capital Management LLC | 1.45M | ▲ 505.46K |
| Vanguard Capital Management LLC | 1.20M | ▲ 234.13K |
| Castleknight Management LP | 1.08M | 0 |
| American Century Companies Inc | 903.60K | ▲ 594.24K |
| Bridgeway Capital Management, LLC | 841.13K | ▼ 89.54K |
| Morgan Stanley | 670.32K | ▲ 354.36K |
Held by 141 ETFs
Biggest fund positions in ARDT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 25, 26 | LUMSDAINE ALFRED | other | 3,389 |
| Sep 25, 26 | Petrovich Stephen C. | other | 788 |
| Sep 25, 26 | Byers David Raynor | other | 524 |
| Jul 1, 26 | Caspers Dave | other | 103,653 |
| Jun 5, 26 | DeMichiei Robert | buy | 11,260 |
| Jun 5, 26 | LUMSDAINE ALFRED | buy | 10,000 |
| Apr 1, 26 | Bulgarelli Peter J. | other | 14,231 |
| Apr 1, 26 | Havdala Ellen | other | 14,231 |
| Apr 1, 26 | Sotir Mark R | other | 14,231 |
| Apr 1, 26 | Sen Rahul | other | 14,231 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARDT coverage
Recent articles, reports, and earnings notes.
No research on ARDT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARDT report →Eight Ardent Health Facilities Earn ‘A' Hospital Safety Grades from The Leapfrog Group for Fall 2026 Grading Period
businesswire.com · Nov 18
Ardent Health Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
businesswire.com · Nov 17
CORRECTING and REPLACING Ardent Health Announces Proposed Secondary Offering of Common Stock and Concurrent Share Repurchase
businesswire.com · Nov 17
Ardent Health Announces Proposed Secondary Offering of Common Stock and Concurrent Share Repurchase
businesswire.com · Nov 17
Ardent Health, Inc. (ARDT) M&A Call Transcript
seekingalpha.com · Nov 14
Ardent Health Announces Definitive Agreement to Acquire Boone Health
businesswire.com · Nov 12
Ardent Health, Inc. (ARDT) Presents at 2026 UBS Global Healthcare Conference Prepared Remarks Transcript
seekingalpha.com · Nov 11
Ardent Health (NYSE:ARDT) Reaches New 12-Month High After Analyst Upgrade
defenseworld.net · Nov 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.